Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Synthetic vitamin A analogue (isotretinoin) awaiting approval for cystic acne therapy

Synthetic vitamin A analogue (isotretinoin) awaiting approval for cystic acne therapy An oral synthetic retinoid, which according to some dermatologists will revolutionize treatment for severe cystic acne, is likely to be available for general clinical use later this year. Isotretinoin 13-cis-retinoic acid) has been recommended for approval by the Food and Drug Administration pending some labeling changes by its manufacturer, Hoffman-La Roche Inc, Nutley, NJ. About one third of the university dermatology centers in the United States have conducted clinical trials with one of several synthetic retinoids, and isotretinoin appears to be the most effective for treating cystic acne, according to Carl Ehmann, MD, director of clinical research for dermatology at Hoffman-La Roche. Isotretinoin has an impressive track record so far: At doses ranging from 0.02 to 2.0 mg/kg/day, dermatologists from the United States and several European countries report that virtually all patients experience complete amelioration of their acne, usually after an eight- to 16-week course of treatment. In http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Synthetic vitamin A analogue (isotretinoin) awaiting approval for cystic acne therapy

JAMA , Volume 247 (13) – Apr 2, 1982

Loading next page...
 
/lp/american-medical-association/synthetic-vitamin-a-analogue-isotretinoin-awaiting-approval-for-cystic-NFi1H30acf

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1982 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1982.03320380006003
Publisher site
See Article on Publisher Site

Abstract

An oral synthetic retinoid, which according to some dermatologists will revolutionize treatment for severe cystic acne, is likely to be available for general clinical use later this year. Isotretinoin 13-cis-retinoic acid) has been recommended for approval by the Food and Drug Administration pending some labeling changes by its manufacturer, Hoffman-La Roche Inc, Nutley, NJ. About one third of the university dermatology centers in the United States have conducted clinical trials with one of several synthetic retinoids, and isotretinoin appears to be the most effective for treating cystic acne, according to Carl Ehmann, MD, director of clinical research for dermatology at Hoffman-La Roche. Isotretinoin has an impressive track record so far: At doses ranging from 0.02 to 2.0 mg/kg/day, dermatologists from the United States and several European countries report that virtually all patients experience complete amelioration of their acne, usually after an eight- to 16-week course of treatment. In

Journal

JAMAAmerican Medical Association

Published: Apr 2, 1982

There are no references for this article.